Evaluation of potential of targeted sequencing through mutational signature simulation
PLOS One · 2025
DOI: 10.1371/journal.pone.0326071 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Keisuke Kodama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Hauptthemen laut MEDLINE: Mutation, Neoplasms, Exome Sequencing. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Targeted sequencing is critical in cancer diagnosis, treatment selection, and monitoring. However, the effectiveness of these methods for reflecting whole-exome sequencing (WES)-level mutational signatures remains unclear. Therefore, we addressed this issue through simulation-based analysis to clarify how well targeted sequencing can reproduce WES-level mutational signatures.
Methods
We compared the correlation and similarity of mutational signatures between whole-exome sequencing-level mutation data and downsampled data for gene sets targeted by each sequencing method in 13 cancer types. Additionally, a similarity analysis of the mutational signatures was conducted using randomly downsampled data.
Results
The comparison between whole-exome sequencing and targeted sequencing showed a low correlation based on Pearson’s correlation coefficient but a high similarity based on the Dice similarity index. As a result of the downsampling of data with cancer-related genes and whole genes to evaluate similarity, the cancer-related gene random set showed high similarity when 200–400 genes were selected. However, the whole-genome random set required 2–3 times as many genes as the cancer-related gene random set to show high similarity. Among cancer types, colorectal and lung cancers demonstrated high similarity with fewer downsampled genes, whereas breast and prostate cancers required more downsampled genes to achieve high similarity.
Conclusion
This study demonstrated that current clinically used targeted sequencing methods can reflect whole-exome sequencing-level mutational signatures. This suggests that considering the cancer type and average number of gene mutations in each patient when selecting targeted sequencing methods can lead to more effective treatment choices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Bioinformatics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
- Medical AI Center, Niigata University School of Medicine, Niigata, Japan.
- Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
ORCID-Profile: Keisuke Kodama, Yiwei Ling, Shujiro Okuda
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Kodama, K., Ling, Y., Ichikawa, H., Wakai, T., & Okuda, S. (2025). Evaluation of potential of targeted sequencing through mutational signature simulation. PLOS One. https://doi.org/10.1371/journal.pone.0326071
Vancouver
Kodama K, Ling Y, Ichikawa H, Wakai T, Okuda S. Evaluation of potential of targeted sequencing through mutational signature simulation. PLOS One. 2025. doi:10.1371/journal.pone.0326071
BibTeX
@article{Kodama2025,
author = {Kodama, Keisuke and Ling, Yiwei and Ichikawa, Hiroshi and Wakai, Toshifumi and Okuda, Shujiro},
title = {Evaluation of potential of targeted sequencing through mutational signature simulation},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0326071}
}
EUVIMED